Human interleukin-6
Also known as: B-cell stimulatory factor 2, BSF-2, BSF‑2, Hepatocyte-stimulating factor, IL-6, Interferon beta-2, Interleukin-6, Interleukin‑6
Source Human interleukin-6 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Recombinant human IL-6 is a 212‑amino‑acid cytokine used experimentally to study immune activation, inflammation, and acute‑phase responses.
Mechanism of Action
Binds IL-6 receptor (IL-6R) and gp130, activating JAK/STAT and MAPK pathways to modulate inflammation and hematopoiesis
Routes of Administration
Goals & Uses
- B-cell and plasma cell differentiation (research)Immunology ResearchHigh
- Immune activationImmunologyModerate
- Hematopoiesis stimulationHematologyModerate
- Thrombocytopenia (chemotherapy-induced) mitigationHematologyLow
- Acute-phase response induction (research model)Research / ImmunologyHigh
- Hematopoiesis supportHematologyModerate
Contraindications
- Active systemic infection or sepsisInfectious DiseaseHigh
- Malignancy (IL-6-dependent tumors)OncologyHigh
- Severe inflammatory diseaseAutoimmuneHigh
- Active autoimmune diseaseAutoimmunityHigh
Adverse Effects
- Injection site reactionsLocalCommon
- AnemiaHematologicUncommonLow red blood cell count or hemoglobin
- HypotensionCardiovascularUncommonLow blood pressure
- Fever / flu-like syndromeSystemicCommon
- FeverSystemicCommonElevated body temperature
- ThrombocytosisHematologyCommon
- Fatigue and malaiseSystemicCommon
Drug Interactions
- CYP450-metabolized drugs (e.g., warfarin, cyclosporine)Moderate
- CorticosteroidsModerate
- Tocilizumab / Sarilumab (IL-6R antagonists)High
Population Constraints
- Pediatric populationsAgeRelative
- Immunocompromised patientsImmunologicRelative
- Pregnant or breastfeeding individualsReproductive SafetyRelative
- Pregnant womenReproductiveRelative
Regulatory Status
- European UnionInvestigationalClinical trial material, not marketed
- United StatesInvestigationalInvestigational New Drug (IND) status for clinical trials only
- United KingdomUnapprovedNot approved by MHRA; research and investigational use only.
Recombinant human IL-6 itself is not an approved drug product in any major jurisdiction. It is used as a research reagent and has been investigated in early-phase trials (e.g., to counteract chemotherapy-induced thrombocytopenia) but development as a therapeutic has largely been superseded by IL-6 pathway antagonists.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Human interleukin-6?
Recombinant human IL-6 is a 212‑amino‑acid cytokine used experimentally to study immune activation, inflammation, and acute‑phase responses.
What is Human interleukin-6 used for?
Human interleukin-6 is educationally associated with: B-cell and plasma cell differentiation (research), Immune activation, Hematopoiesis stimulation, Thrombocytopenia (chemotherapy-induced) mitigation, Acute-phase response induction (research model), Hematopoiesis support. Educational only — not medical advice.
How is Human interleukin-6 administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Human interleukin-6?
Reported adverse effects include: Injection site reactions, Anemia, Hypotension, Fever / flu-like syndrome, Fever, Thrombocytosis, Fatigue and malaise. This list is not exhaustive — consult a qualified clinician.
Who should avoid Human interleukin-6?
Recorded contraindications: Active systemic infection or sepsis, Malignancy (IL-6-dependent tumors), Severe inflammatory disease, Active autoimmune disease. Consult a qualified clinician before use.